D. E. Shaw & Co., Inc. Crispr Therapeutics Ag Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 59,300 shares of CRSP stock, worth $2.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

59,300

Holding current value

$2.34 Million

% of portfolio

0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $53,142 - $74,735	1,191 Added 4.23%	29,365 $1.38 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $7.48 Million - $9.96 Million	-146,121 Reduced 83.84%	28,174 $1.52 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $8.31 Million - $12.2 Million	137,023 Added 367.63%	174,295 $11.9 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $1.44 Million - $2.69 Million	37,272 New	37,272 $2.33 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $381,300 - $521,916	-9,300 Reduced 66.91%	4,600 $208,000
Q4 2022 Feb 14, 2023	BUY	$39.19 - $65.67 $544,741 - $912,813	13,900 New	13,900 $565,000
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $768,489 - $1.14 Million	14,448 Added 62.35%	37,620 $2.36 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $807,717 - $1.28 Million	-11,524 Reduced 33.21%	23,172 $1.76 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $1.08 Million - $1.53 Million	9,798 Added 39.35%	34,696 $3.88 Million
Q2 2021 Aug 16, 2021	SELL	$100.84 - $161.89 $5.27 Million - $8.47 Million	-52,294 Reduced 67.75%	24,898 $4.03 Million
Q1 2021 May 17, 2021	SELL	$110.72 - $210.04 $22.8 Million - $43.3 Million	-205,959 Reduced 72.74%	77,192 $9.41 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $1.3 Million - $2.82 Million	16,284 Added 6.1%	283,151 $43.4 Million
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $4.85 Million - $6.22 Million	-61,757 Reduced 18.79%	266,867 $22.3 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $2.03 Million - $4.01 Million	52,765 Added 19.13%	328,624 $24.2 Million
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $9 Million - $16.7 Million	267,192 Added 3082.87%	275,859 $11.7 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $418,775 - $834,925	-11,417 Reduced 56.85%	8,667 $528,000
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $535,534 - $686,696	13,065 Added 186.14%	20,084 $823,000
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $16,555 - $22,509	467 Added 7.13%	7,019 $331,000
Q1 2019 May 15, 2019	SELL	$28.02 - $40.87 $508,843 - $742,199	-18,160 Reduced 73.49%	6,552 $234,000
Q4 2018 Feb 14, 2019	BUY	$22.73 - $42.34 $435,893 - $811,954	19,177 Added 346.47%	24,712 $706,000
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $6,741 - $9,987	-152 Reduced 2.67%	5,535 $245,000
Q2 2018 Aug 14, 2018	SELL	$42.62 - $73.59 $439,326 - $758,565	-10,308 Reduced 64.45%	5,687 $334,000
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $376,202 - $930,429	15,995 New	15,995 $731,000

Others Institutions Holding CRSP

# of Institutions

489

Shares Held

58.8M

Call Options Held

1.09M

Put Options Held

1.9M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.07B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account